JP2017510590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510590A5 JP2017510590A5 JP2016559366A JP2016559366A JP2017510590A5 JP 2017510590 A5 JP2017510590 A5 JP 2017510590A5 JP 2016559366 A JP2016559366 A JP 2016559366A JP 2016559366 A JP2016559366 A JP 2016559366A JP 2017510590 A5 JP2017510590 A5 JP 2017510590A5
- Authority
- JP
- Japan
- Prior art keywords
- spiro
- methyl
- dihydro
- triaza
- diaza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2,8-diaza-spiro [4.5] decan-1-one-yl Chemical group 0.000 claims 122
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000000066 myeloid cell Anatomy 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- AVQXDJUHGDOBKN-UHFFFAOYSA-N 1-methyl-3h-2,1-benzothiazole Chemical compound C1=CC=C2N(C)SCC2=C1 AVQXDJUHGDOBKN-UHFFFAOYSA-N 0.000 claims 1
- NYLGITXFVVEBLZ-UHFFFAOYSA-N 1-methylindazol-3-amine Chemical group C1=CC=C2N(C)N=C(N)C2=C1 NYLGITXFVVEBLZ-UHFFFAOYSA-N 0.000 claims 1
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 1
- KZHXHOJTGTURDJ-UHFFFAOYSA-N 1h-indazol-3-ylcarbamic acid Chemical compound C1=CC=C2C(NC(=O)O)=NNC2=C1 KZHXHOJTGTURDJ-UHFFFAOYSA-N 0.000 claims 1
- UATCBIAFFSRLBH-UHFFFAOYSA-N 2-tert-butyl-3h-1,2-benzothiazole Chemical compound C1=CC=C2SN(C(C)(C)C)CC2=C1 UATCBIAFFSRLBH-UHFFFAOYSA-N 0.000 claims 1
- FPWYXHKGPQQAAG-UHFFFAOYSA-N 3-oxodecanal Chemical compound CCCCCCCC(=O)CC=O FPWYXHKGPQQAAG-UHFFFAOYSA-N 0.000 claims 1
- MPEFBGVVCCHQRA-UHFFFAOYSA-N 8-[3-chloro-5-(1-methylindazol-5-yl)pyridin-4-yl]-2,8-diazaspiro[4.5]decane-1,3-dione Chemical compound ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C=1C=C2C=NN(C2=CC1)C MPEFBGVVCCHQRA-UHFFFAOYSA-N 0.000 claims 1
- OKKQGSQYZMIETI-UHFFFAOYSA-N C(C)(C)N1N=CC(=C1)C1=CC=C(C=C1)C=1C=NC=C(C=1N1CCC2(CNC(O2)=O)CC1)C(F)(F)F Chemical compound C(C)(C)N1N=CC(=C1)C1=CC=C(C=C1)C=1C=NC=C(C=1N1CCC2(CNC(O2)=O)CC1)C(F)(F)F OKKQGSQYZMIETI-UHFFFAOYSA-N 0.000 claims 1
- OMUNPUZBDSTLJV-UHFFFAOYSA-N CN1N=CC(=C1)C1=CC=C(C=C1)C=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C(F)(F)F Chemical compound CN1N=CC(=C1)C1=CC=C(C=C1)C=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C(F)(F)F OMUNPUZBDSTLJV-UHFFFAOYSA-N 0.000 claims 1
- VZGUYBWECPUEAQ-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(N=C(N2)C)=O)CC1)C=1C=C2C=NN(C2=CC1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(C(N=C(N2)C)=O)CC1)C=1C=C2C=NN(C2=CC1)C VZGUYBWECPUEAQ-UHFFFAOYSA-N 0.000 claims 1
- GBYCDBFSAXCWDG-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(NC(N2)=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(C(NC(N2)=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 GBYCDBFSAXCWDG-UHFFFAOYSA-N 0.000 claims 1
- TYCOTTAYUVNCMS-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(NC(N2)=O)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(C(NC(N2)=O)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C TYCOTTAYUVNCMS-UHFFFAOYSA-N 0.000 claims 1
- SOGOUJPVOZWDFQ-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(NCC(N2)=O)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(C(NCC(N2)=O)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C SOGOUJPVOZWDFQ-UHFFFAOYSA-N 0.000 claims 1
- ZLJBWVWHTDCWFO-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(NCN2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(C(NCN2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C ZLJBWVWHTDCWFO-UHFFFAOYSA-N 0.000 claims 1
- ZHRPMMZXBYARRJ-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C1=CC2=C(NS(C2)(=O)=O)C=C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C1=CC2=C(NS(C2)(=O)=O)C=C1 ZHRPMMZXBYARRJ-UHFFFAOYSA-N 0.000 claims 1
- BNUILOFXARRTCB-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C1=CC=C2C=NN(C2=C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C1=CC=C2C=NN(C2=C1)C BNUILOFXARRTCB-UHFFFAOYSA-N 0.000 claims 1
- KBJLGGRKCRPTBK-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CCNC2=O)CC1)C1=CC2=C(S(CC2O)(=O)=O)C=C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(CCNC2=O)CC1)C1=CC2=C(S(CC2O)(=O)=O)C=C1 KBJLGGRKCRPTBK-UHFFFAOYSA-N 0.000 claims 1
- IZIZTVUBBXGCPR-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CCNC2=O)CC1)C1=CC=C(C=C1)C=1N=C(N(C1)C)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CCNC2=O)CC1)C1=CC=C(C=C1)C=1N=C(N(C1)C)C IZIZTVUBBXGCPR-UHFFFAOYSA-N 0.000 claims 1
- ZNMSRFYDOSAZLZ-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 ZNMSRFYDOSAZLZ-UHFFFAOYSA-N 0.000 claims 1
- AOIKBYAXRMABCX-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=CN(N=C2C=C1)C(C)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=CN(N=C2C=C1)C(C)C AOIKBYAXRMABCX-UHFFFAOYSA-N 0.000 claims 1
- IRRYSPITUYJSDM-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=CN(N=C2C=C1)CC Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=CN(N=C2C=C1)CC IRRYSPITUYJSDM-UHFFFAOYSA-N 0.000 claims 1
- FCYOCMIKYSONQM-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CC(C)(C)O Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CC(C)(C)O FCYOCMIKYSONQM-UHFFFAOYSA-N 0.000 claims 1
- SIBZRLUQLOVPGB-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CCO Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CCO SIBZRLUQLOVPGB-UHFFFAOYSA-N 0.000 claims 1
- NKKSTXMWBZRFCS-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CCS(=O)(=O)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CCS(=O)(=O)C NKKSTXMWBZRFCS-UHFFFAOYSA-N 0.000 claims 1
- MGWQJHKQHJNDKH-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C2C=NN(C2=C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C2C=NN(C2=C1)C MGWQJHKQHJNDKH-UHFFFAOYSA-N 0.000 claims 1
- XPWYZFKMRUWIDU-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C=1C=CC2=C(NC(O2)=O)C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C=1C=CC2=C(NC(O2)=O)C1 XPWYZFKMRUWIDU-UHFFFAOYSA-N 0.000 claims 1
- NALGKDPHSMQYFA-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(C(NC(=N2)C)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C=1N1CCC2(C(NC(=N2)C)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 NALGKDPHSMQYFA-UHFFFAOYSA-N 0.000 claims 1
- ISJQYDFLDROVOP-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(C(NCC(N2)=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C=1N1CCC2(C(NCC(N2)=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 ISJQYDFLDROVOP-UHFFFAOYSA-N 0.000 claims 1
- JLLOYHKVHLPRJA-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(C(NCCN2)=O)CC1)C=1C=CC2=C(NC(O2)=O)C=1 Chemical compound ClC=1C=NC=C(C=1N1CCC2(C(NCCN2)=O)CC1)C=1C=CC2=C(NC(O2)=O)C=1 JLLOYHKVHLPRJA-UHFFFAOYSA-N 0.000 claims 1
- KILPTFZHIBCKGZ-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(CC(NC2=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C=1N1CCC2(CC(NC2=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 KILPTFZHIBCKGZ-UHFFFAOYSA-N 0.000 claims 1
- LIFXRRLDZMTTKU-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(CNC(O2)=O)CC1)C=1C=C2CC(N(C2=CC=1)C)=O Chemical compound ClC=1C=NC=C(C=1N1CCC2(CNC(O2)=O)CC1)C=1C=C2CC(N(C2=CC=1)C)=O LIFXRRLDZMTTKU-UHFFFAOYSA-N 0.000 claims 1
- VOFNJBCAXJKFQM-UHFFFAOYSA-N NC1=NNC2=CC(=CC=C12)C=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)Cl Chemical compound NC1=NNC2=CC(=CC=C12)C=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)Cl VOFNJBCAXJKFQM-UHFFFAOYSA-N 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000006242 amine protecting group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- SXOVJOBXZPCKRA-UHFFFAOYSA-N spiro[1h-indole-3,4'-piperidine]-2-one Chemical compound O=C1NC2=CC=CC=C2C11CCNCC1 SXOVJOBXZPCKRA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14001145.3 | 2014-03-27 | ||
| EP14001145 | 2014-03-27 | ||
| PCT/EP2015/000528 WO2015144290A1 (en) | 2014-03-27 | 2015-03-10 | Pyridyl piperidines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510590A JP2017510590A (ja) | 2017-04-13 |
| JP2017510590A5 true JP2017510590A5 (cg-RX-API-DMAC7.html) | 2018-04-19 |
| JP6434989B2 JP6434989B2 (ja) | 2018-12-05 |
Family
ID=50389770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559366A Expired - Fee Related JP6434989B2 (ja) | 2014-03-27 | 2015-03-10 | ピリジルピペリジン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9926319B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3122739B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6434989B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106458992B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015236855B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2943659C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2720324T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL247728B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015144290A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6447304B2 (ja) * | 2015-03-27 | 2019-01-09 | Jsr株式会社 | 液晶配向剤、液晶配向膜及びその製造方法、液晶表示素子、位相差フィルム及びその製造方法、重合体並びに化合物 |
| BR112017025851A2 (pt) | 2015-06-01 | 2018-10-16 | Bantam Pharmaceutical, Llc | compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo |
| CN108348509A (zh) * | 2015-11-03 | 2018-07-31 | Lu许可公司 | 用于治疗增殖减少性病症的化合物 |
| CA3082011A1 (en) | 2016-11-30 | 2018-06-07 | Bantam Pharmaceutical, Llc | Methods of using substituted pyrazole and pyrrole compounds and for treatment of hyperproliferative diseases |
| US11325903B2 (en) * | 2016-11-30 | 2022-05-10 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| ES3004107T3 (en) | 2017-01-30 | 2025-03-11 | Univ Kyoto | Novel compound, and method for producing regulatory t cells |
| US11261184B2 (en) | 2017-10-02 | 2022-03-01 | Boehringer Ingelheim International Gmbh | [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors |
| WO2021126725A1 (en) * | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Novel substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors |
| US20240400993A1 (en) | 2021-09-27 | 2024-12-05 | Kyoto University | Method for producing t cell |
| JP7572755B2 (ja) | 2021-11-24 | 2024-10-24 | レグセル株式会社 | ヒト誘導性制御性ｔ細胞およびその作製方法 |
| TW202334397A (zh) | 2021-11-24 | 2023-09-01 | 日商雷格細胞股份有限公司 | 用於治療或預防t細胞相關疾病之醫藥組合物 |
| CN119256076A (zh) | 2022-03-23 | 2025-01-03 | 国立大学法人京都大学 | 用于产生调节性t细胞的方法 |
| WO2024071039A1 (ja) | 2022-09-26 | 2024-04-04 | レグセル株式会社 | キメラ抗原受容体（ｃａｒ）を含む誘導性制御性ｔ細胞 |
| AU2023353929A1 (en) | 2022-09-26 | 2025-05-01 | Kyoto University | T cell production method |
| EP4663195A1 (en) | 2023-02-08 | 2025-12-17 | Regcell Co., Ltd. | Pharmaceutical composition for treating or preventing pemphigus |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| AU2011328074B2 (en) * | 2010-11-12 | 2016-05-05 | Deutsches Krebsforschungszentrum (Dkfz) | Chromene derivatives and their analoga as Wnt pathway antagonists |
| PH12017500997A1 (en) * | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| EP2770994B1 (en) * | 2012-05-04 | 2019-08-21 | Samumed, LLC | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| EP2912037B1 (en) * | 2012-10-08 | 2018-08-22 | Merck Patent GmbH | 2-aminopyridine compounds |
-
2015
- 2015-03-10 US US15/129,338 patent/US9926319B2/en active Active
- 2015-03-10 ES ES15709097T patent/ES2720324T3/es active Active
- 2015-03-10 CN CN201580027519.1A patent/CN106458992B/zh not_active Expired - Fee Related
- 2015-03-10 CA CA2943659A patent/CA2943659C/en active Active
- 2015-03-10 AU AU2015236855A patent/AU2015236855B2/en not_active Ceased
- 2015-03-10 EP EP15709097.8A patent/EP3122739B1/en not_active Not-in-force
- 2015-03-10 WO PCT/EP2015/000528 patent/WO2015144290A1/en not_active Ceased
- 2015-03-10 JP JP2016559366A patent/JP6434989B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-08 IL IL247728A patent/IL247728B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510590A5 (cg-RX-API-DMAC7.html) | ||
| TWI879728B (zh) | Shp2磷酸酶抑制劑及其使用方法 | |
| JP2016500694A5 (cg-RX-API-DMAC7.html) | ||
| JP6631616B2 (ja) | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 | |
| DE60208792T2 (de) | Tyrosin-kinase inhibitoren | |
| KR102485100B1 (ko) | 치환된 우레아 유도체 및 이의 약제학적 용도 | |
| EP2953940B1 (en) | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists | |
| EP4010335A1 (en) | Shp2 inhibitors | |
| US20200172546A1 (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
| BR112019018991A2 (pt) | compostos e composições para tratar distúrbios hematológicos | |
| JP2013539777A5 (cg-RX-API-DMAC7.html) | ||
| AU1091301A (en) | Tyrosine kinase inhibitors | |
| JP2019508384A (ja) | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| JP2010513495A (ja) | 新規なｊｎｋ阻害剤 | |
| WO2003009852A1 (en) | Tyrosine kinase inhibitors | |
| JP2010535201A (ja) | 抗癌治療としての抗有糸分裂薬およびオーロラキナーゼ阻害薬 | |
| KR20150120383A (ko) | 신규 피라졸 유도체 | |
| KR20160056896A (ko) | Ｐｉｍ 키나아제 억제제로서 유용한 푸로- 및 티에노-피리딘 카복사미드 화합물 | |
| AU2013243020A1 (en) | Cyclic amides as MetAP-2 inhibitors | |
| WO2012082689A1 (en) | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | |
| TW201822764A (zh) | Syk抑制劑 | |
| AU2011344001A1 (en) | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | |
| WO2014151936A9 (en) | Octahydropyrrolopyrroles, their preparation and use | |
| KR20230107419A (ko) | 암 치료 방법 | |
| WO2013117645A1 (en) | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |